The stock has a 36-month beta value of 1.61. Opinions on the stock are mixed, with 3 analysts rating it as a “buy”, 0 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for NRXP is 16.17M, and at present, short sellers hold a 7.40% of that float. On July 04, 2025, the average trading volume of NRXP was 260.64K shares.
NRXP stock’s latest price update
The stock of NRX Pharmaceuticals Inc (NASDAQ: NRXP) has increased by 1.81% when compared to last closing price of $3.32. Despite this, the company has experienced a -3.43% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-26 that Cohen and Associates is a highly respected neuropsychiatry clinic in western Florida Cohen to serve as foundational clinic in the Sarasota – Bradenton area of Florida Acquisition expected to be immediately accretive to revenue and EBITDA MIAMI, June 26, 2025 /PRNewswire/ — HOPE Therapeutics™, Inc. (“HOPE”), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the signing of a binding Letter of Intent (the “LOI”) to purchase a 49% interest in Cohen and Associates, LLC (“Cohen”), founded by Dr. Rebecca Cohen. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida.
NRXP’s Market Performance
NRXP’s stock has fallen by -3.43% in the past week, with a monthly rise of 24.26% and a quarterly rise of 68.16%. The volatility ratio for the week is 6.15% while the volatility levels for the last 30 days are 8.11% for NRX Pharmaceuticals Inc The simple moving average for the past 20 days is 1.20% for NRXP’s stock, with a 54.13% simple moving average for the past 200 days.
Analysts’ Opinion of NRXP
Many brokerage firms have already submitted their reports for NRXP stocks, with BTIG Research repeating the rating for NRXP by listing it as a “Buy”. The predicted price for NRXP in the upcoming period, according to BTIG Research is $18 based on the research report published on April 02, 2025 of the current year 2025.
NRXP Trading at 23.50% from the 50-Day Moving Average
After a stumble in the market that brought NRXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.76% of loss for the given period.
Volatility was left at 8.11%, however, over the last 30 days, the volatility rate increased by 6.15%, as shares surge +14.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +76.96% upper at present.
During the last 5 trading sessions, NRXP fell by -3.43%, which changed the moving average for the period of 200-days by +96.51% in comparison to the 20-day moving average, which settled at $3.34. In addition, NRX Pharmaceuticals Inc saw 31.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRXP starting from Javitt Jonathan C, who purchase 40,000 shares at the price of $1.17 back on Dec 17 ’24. After this action, Javitt Jonathan C now owns 84,634 shares of NRX Pharmaceuticals Inc, valued at $46,800 using the latest closing price.
N/A, the N/A of NRX Pharmaceuticals Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for NRXP
Current profitability levels for the company are sitting at:
- -4087.75% for the present operating margin
- 0.25% for the gross margin
The net margin for NRX Pharmaceuticals Inc stands at -6027.5%. The total capital return value is set at 0.65%.
Currently, EBITDA for the company is -18.5 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 15093.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
To sum up, NRX Pharmaceuticals Inc (NRXP) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
